RPX7009

DRUG3 trials

Sponsors

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Conditions

Bacterial InfectionsHealthy Volunteers

Phase 1

Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects

CompletedNCT01751269

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Bacterial Infections, Healthy Volunteers

Start: 2012-12-31End: 2013-07-31Updated: 2013-07-24

Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination

CompletedNCT01772836

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Bacterial Infections, Healthy Volunteers

Start: 2013-03-31End: 2013-03-31Target: 30Updated: 2013-07-11

Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects

CompletedNCT01897779

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)Bacterial Infections, Healthy Volunteers

Start: 2013-07-31End: 2014-02-28Updated: 2014-04-29

Related Papers

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy2018-01-3151 citations

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy2016-08-1678 citations